Sultanova A, Viksna L, Murovska M: Activation of human herpesviruses 6 and 7 in patients with chronic fatigue syndrome. J Clin Virol 2006, S47–51.

. Movie C0m %C5%B7%C3%C0%D0%D4%B0%AE%C7%F8 r%C www.yyq1220.com%AE %C5%B7%C3%C0%D0%D4%B0%AE%C7%F8 BE Sex A Milflatinlover %search2%searchC Milflatinlover C7 Sexy BF%searchC%Esearch% Movie 02B8searchD6searchDsearch%B Movie % Movie 8nsearchBsearch searchl Sexy m

n Sexy search, Milflatinlover J Milflatinlover wsearchn Sexy DVDPS-902,

M Milflatinlover d

e Sex d %C5%B7%C3%C0%D0%D4%B0%AE%C7%F8 r Milflatinlover search, Milflatinlover Nwww.yyq1220.comisearchgsearchZ Milflatinlover nna.Apprentie.Soubrettea Milflatinlover li

s %C5%B7%C3%C0%D0%D4%B0%AE%C7%F8 n W

%C5%B7%C3%C0%D0%D4%B0%AE%C7%F8 b Sexy awww.jizzut.comh

Sex ,searchL Sexy o Movie dsearchA:searchS Movie r Sexy l Movie g %C5%B7%C3%C0%D0%D4%B0%AE%C7%F8 c %C5%B7%C3%C0%D0%D4%B0%AE%C7%F8 l Sexy a Sex d Sexy vi

o Movie og Milflatinlover ca Sex i Movie vsearchst

gwww.1milf1dream.comtsearcho %C5%B7%C3%C0%D0%D4%B0%AE%C7%F8 Sex fsearchtsearchesearchr Milflatinlover l Sex Sexy f searchh

e Sexy v %C5%B7%C3%C0%D0%D4%B0%AE%C7%F8 r

EsearchVsearch

M%D5%FD%CF%DF%BA%AB%B9%FA%D0%D4%B0%AE%B3%C7+%BF%EC%B2%A5,%BD%DD%BF%CB%C2%DB%CC%B3+%B7%D6%CF%ED%C4%E3%B5%C4%CA%C0%BD%E7asearchd HDVDES402V-6

i Sex Milflatinlover osearcht Sex in Milflatinlover ec Sex ivsearch %C5%B7%C3%C0%D0%D4%B0%AE%C7%F8 asearchisearchusearch Sex y %C5%B7%C3%C0%D0%D4%B0%AE%C7%F8 dsearchosearche. Sexy J Milflatinlover e

o Milflatinlover search01search,search81:search68 Sex � Sex �168 Sexy .
27. Moss-Morris R, Spence M: To “lump” or to “split” the functional somatic syndrome: can infectious and emotional risk factors differentiate between the onset of chronic fatigue syndrome and irritable bowel syndrome? Psychol Med 2006, 68:463–469.
28. Khan AS, Heneine WM, Chapman LE, Gary HE Jr, Woods TC, Folks TM, Schonberger LB: Assessment of a retrovirus sequence and other possible risk factors for the chronic fatigue syndrome in adults. Ann Intern Med 1993, 118:241–245.
29. Lombardi VC, Ruscetti FW, Das Gupta J, Pfost MA, Hagen KS, Peterson DL, Ruscetti SK, Bagni RK, Petrow- Sadowski C, Gold B, Dean M, Silverman RH, Mikovits JA: Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science 2009, 326:585–589.
30. Erlwein O, Kaye S, McClure MO, Weber J, Wills G, Collier D, Wessely S, Cleare A: Failure to detect the novel retrovirus XMRV in chronic fatigue syndrome. PLOS One 2010, 5:e8519.
31. Groom HC, Boucherit VC, Makinson K, Randal E, Baptista S, Hagan S, Gow JW, Mattes FM, Breuer J, Kerr JR, Stoye JP, Bishop KN: Absence of xenotropic murine leukemia virus-related virus in UK patients with chronic fatigue syndrome. Retrovirology 2010, 7:10.
32. van Kuppeveld FJ, Jong AS, Lanke KH, Verhaegh GW, Melchers WJ, Swanink CM, Bleijenberg G, Netea MG, Galama JM, van der Meer JW: Prevalence of xenotropic murine leukemia virus-related virus in patients with chronic fatigue syndrome in the Netherlands: retroscpective analysis of samples from an established cohort.
BMJ 2010, 340:c1018.
33. Hong P, Li J, Li Y: Failure to detect Xenotropic murine leukaemia virus-related virus in Chinese patients with chronic fatigue syndrome. Virol J 2010, 7:224.
34. Switzer WM, Jia H, Hohn O, Zheng H-Q, Tang S, Shankar A, Bannert N, Simmons G, Hendry RM, Falkenberg
VR, Reeves WC, Heneine W: Absence of evidence of xenotropic murine leukemia virus-related virus infection in persons with chronic fatigue syndrome and healthy controls in the United States. Retrovirology 2010, 7:57.
35. Zachrisson O, Regland B, Jahreskog M, Kron M, Gottfries CG: A rating scale for fibromyalgia and chronic fatigue syndrome (the FibroFatigue scale). J Psychosom Res 2002, 52:501–509.
36. Cani D, Possemiers S, Van De Wiele T, Guiot Y, Everard A, Rottier O, Geurts L, Naslain D, Neyrinck A, Lambert DM, et al.: Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet induced obesity and diabetes in mice. Diabetes 2008, 57:1470–1481.
37. Wu GH, Wang H, Zhang YW, Wu ZH, Wu ZG: Glutamine supplemented parenteral nutrition prevents intestinal ischemia-reperfusion injury in rats. World J Gastroenterol 2004, 10:2592–2594.
38. Jimenez M: Treatment of irritable bowel syndrome with probiotics. An etiopathogenic approach at last? Rev Esp Enferm Dig (Madrid) 2009, 101:553–564.
39. Swidsinski A, Ladhoff A, Pernthaler A, et al.: Mucosal flora in inflammatory bowel disease. Gastroenterology 2002, 122:44–54.
40. Bailey MT, Lubach G, Coe CL: Prenatal stress alters bacterial colonization of the gut in infant monkeys. J Pediatr Gastroenterol Nutr 2004, 38:414–421.
41. Riedel CU, Foata F, Phillippe D, Adolfsson O, Eikmanns BJ, Blum S: Anti-inflammatory effects of bifidobacteria by inhibition of LPS-induced NF-kappaB activation. World J Gastroenterol 2006, 12:3729–3735. Bailey MT, Coe C: Maternal separation disrupts the integrity of the intestinal microflora in infant rhesus monkeys. Dev Psychobiol 1999, 35:146–155.
43. Tannock GW, Savage D: Influences of dietary and environmental stress on microbial populations in the murine gastrointestinal tract. Infect Immun 1974, 9:591–598.
44. Suzuki K, Harasawa R, Yoshitake Y, Mitsuoka T: Effects of crowding and heat stress on intestinal flora, body weight gain, and feed efficiency of growing rats and chicks. Nippon Jujigaku Zasshi 1983, 45:331–338.
45. Butt HL, Dunstan R, McGregor NR, Roberts Tk: Bacterial colonosis in patients with persistent fatigue. In Proceedings of the AHMF international clinical and scientific conference. Sydney, Australia; 2001.
46. Cani D, Possemiers S, Van De Wiele T, Guiot Y, Everard A, Rottier O, Geurts L, Naslain D, Neyrinck A, Lambert DM, Muccioli GG, Delzenne NM: Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-drive improvement of gut permeability. Gut 2009, 58:1091–1103.
47. Chen C, Brown DR, Xie Y, et al.: Catecholamines modulate Escherichia coli O157:H7 adherence to murine cecal mucosa. Shock 2003, 20:183–188.
48. Zhou Q, Zhang B, Verne GN: Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain 2009, 146:41–46.
49. Lee KJ, Tack J: Altered intestinal microbiota in irritable bowel syndrome. Neurgastroenterol Motil 2010, 22:493–498.
50. Ohland CL, Wallace KM: Probiotic bacteria and intestinal epithelial barrier function. Am J Physiol Gastrointest Liver Physiol 2010, 298:G807–G819.
51. Aragon G, Aragon D, Borum M, Doman DB: Probiotic therapy for irritable bowel syndrome. Gastroenterol Hepatol 2010, 6:39–44.
52. Guyonnet D, Chassany O, Ducrotte P, Picard C, Mouret M, et al.: Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a mulicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 2007, 26:475–486.
53. Rao AV, Bested AC, Beaulne TM, Katzman MA, Iorio C, Berardi JM, Logan AC: A randomized double-blind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome. Gut Pathogens 2009, 6.
54. Phillips J: The treatment of melancholia by the lactic acid 55. bacillus. J Mental Sci 1910, 56:422–431.
Raison CL, Lin JM, Reeves WC: Association of peripheral inflammatory markers with chronic fatigue in a population-based sample. Brain Behav Immun 2009, 23:327–337.
56. Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW: From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008, 9:46–56.
57. Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB, Miller AH: Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropscyhopharmacology 2002, 26:643–652.
58. Lyall M, Peakman M, Wessely S: A systematic review and critical evaluation of the immunology of chronic fatigue syndrome. J Psychosom Res 2003, 55:79–90.
59. Klimas NG, Koneru AO: Chronic fatigue syndrome: inflammation, immune function and neuroendocrine interactions. Curr Rheum Rep 2007, 9:482–487.
60. Natelson BH, Haghighi MH, Ponzio NM: Evidence for the presence of immune dysfunction in chronic fatigue syndrome. Clin Diagn Lab Immunol 2002, 9:747–752.
61. van Langenberg DR, Gibson PR: Systematic review: fatigue in inflammatory bowel disease. Aliment Pharmacol Ther 2010, 32:131–143.
62. Lamprecht K: Pilot study of etanercept treatment in patients with chronic fatigue syndrome. In Meeting of the Amercian Associations of Chronic Fagitue Syndrome (AACFS). Seattle; 2001.
63. Powell R, Ren J, Lewith G, et al.: Identification of novel expressed sequences, upregulated in the leucocytes of chronic fatigue syndrome patients. Clin Exp Allergy 2003, 33:1450–1456.
64. Kerr JR, Christian P, Hodgetts A, Langford PR, Devanur LD, Petty R, Burke B, Sinclair LI, Richards SCM, Montgomery J, McDermott CR, Harrison TJ, Kellan P, Nutt DJ, Holgate ST, the Collaborative Clinical Study Group: Current research priorities in chronic fatigue syndrome/myalgic encephalomyelitis: disease mechanisms, a diagnostic test and specific treatments. J Clin Pathol 2007, 60:113–116. Broderick G, Fuite J, Kreitz A, Vernon SD, Klimas N, Fletcher MA: A formal analysis of cytokine networks in chronic fatigue syndrome. Brain Behav Immun 2010.
66. Furness JB: The enteric nervous system: normal functions and enteric neuropathies. Neurogastroenterol Motil 2008, 20(1):32–38.
67. Geboes K, Collins S: Structural abnormalities of the nervous system in Crohn’s disease and ulcerative colitis. Neurogastroenterol Motil 1998, 10:189–202.
68. Villanacci V, Bassotti G, Nascimbeni R, Antonelli E, Cadei M, Fisogni S, Salerni B, Geboes K: Enteric nervous system abnormalities in inflammatory bowel disease. Neurogastroenterol Motil 2008, 20:1009–1016.
69. Dvorak AM, Onderdonk AB, McLeod RS, Monahan-Earley RA, Cullen J, Antonioli DA, Blair JE, Morgan ES, Cisneros RL, Estrella P, et al.: Axonal necrosis of enteric autonomic nerves in continent ileal pouches. Possible implications for pathogenesis of Crohn’s disease. Ann Surg 1993, 217:260–271.
70. Tornblom H, Lindberg G, Nyberg B, Veress B, et al.: Full-thickness biopsy of jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 2002, 123:1972–1979.
71. De Giorgio R, Camilleri M: Human enteric neuropathies: morphology and molecular pathology. Neurogastroenterol Motil 2004, 16:515–531.
72. Lakhan SE, Kirchgessner A: Neuroinflammation in inflammatory bowel disease. 73. J Neuroinflam 2010, 7:37. Sido B, Hack V, Hochlehnert A, Lipps H, Herfarth C, Droge W: Impairment of intestinal glutathione synthesis in patients with inflammatory bowel disease. Gut 1998, 42:485–492.
74. Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E: Increased 8-hydroxydeoxyguanosine, a marker of oxidative damage to DNA, in major depression and myalgic encephalomyelitis/chronic fatigue syndrome. Neuro Endocrinol Lett 2009, 30:715–722.
75. Maes M, Twisk FNM: Chronic fatigue syndrome: Harvey and Wessely’s (bio)psychosocial model versus a bio(psychosocial) model based on inflammatory and oxidative and nitrosative stress pathways. BMC Medicine 2010, 8:35.
76. Wagner F, Asfar P, Calzia E, Radermache P, Szabo C: Bench-to-bedside review: hydrogen sulfide – the third gaseous transmitter: applications for critical care. Critical Care 2009, 13:213.
77. Reiffenstein RJ, Hulbert WC, Roth SH: Toxicology of hydrogen sulfide. Annu Rev Pharmacol Toxicol 1992, 32:109–134.
78. Lowicka E, Beltowski J: Hydrogen sulfide (H2S)- the third gas of interest for pharmacologists. Pharmacol Reports 2007, 59:4–24.
79. Fiorucci S, Distrutti E, Cirinio G, Wallace JL: The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver. Gastroenterology 2006, 131:259–271.
80. Ishii I, De Giorgio R, Campi B, Schemann M: Hydrogen sulfide is a novel prosecretory neuromodulator in the guinea-pig and human colon. Gastroenterology 2006, 131:1542–1552.
81. Myhill S, Booth NE, McLaren-Howard J: Chronic fatigue syndrome and mitochondrial dysfunction. Int J Clin Med 2009, 2:1–16.
82. Sheedy JR, Wettenhall R, Scanlon D, Gooley PR, Lewis DP, McGregor N, Stapleton DI, Butt HL, de Meirleir KL: Increased d-lactic acid intestinal bacteria in patients with chronic fatigue syndrome. In Vivo 2009, 23:621–628.
83. Jammes Y, Steinberg JG, Mambrini O, Bregeon F, Delliaux S: Chronic fatigue syndrome: assessment of increased oxidative stress and altered muscle excitability in response to incremental exercise. J Intern Med 2005, 299–310.
84. Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E: Coenzyme Q10 deficiency in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is related to fatigue, autonomic and neurocognitive symptoms and is another risk fact explaining the early mortality in ME/CFS due to cardiovascular disorder. Neuro Endocrinol Lett 2009, 30:470–476.
85. Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E: Lower plasma coenzyme Q10 in depression: a marker for treatment resistance and chronic fatigue in depression and a risk factor to cardiovascular disorder in that illness. Neuro Endocrinol Lett 2009, 30:462–469.
86.
87. Liu C, Russell RM, Smith DE, Bronson RT, Milibury PE, Furukawa S, Wang XD, Blumberg JB: The effect of dietary glutathione and coenzyme Q10 on the prevention and treatment of inflammatory bowel disease in mice. Int J Vitam Nutr Res 2004, 74:74–85.
Abbreviations
CDC: Centers for Disease Control; CFS: chronic fatigue syndrome; CoQ10: coenzyme Q10; CRH: corticotrophin-release hormone; COX-2: cyclooxygenase-2; ENS: enteric nervous system; EBV: Epstien-Barr virus; GI: gastrointestinal; GSH: glutathione hypothalamicpituitary-adrenal; HPA: human parvovirus B19; HPV: human herpes virus-6; HHV-6: human T-lymphotropic virus type 2; HTLV-2: hydrogen sulfide; H2S: inducible nitric oxide synthase; iNOS: inflammatory bowel disease; IBD: irritable bowel syndrome; IBS: interleukin-6; IL-6: interleukin 8; IL-8: interleukin1-beta; IL1-β: interferon-gamma; IFN-γ: interferon-beta; IFN-β: lipopolysaccarhide; LPS: natural killer; NK: nuclear factor-kappa B; NF-κB: peripheral blood mononuclear cell; PBMC: reactive oxygen species; ROS: tissue transglutaminase; tTG: tumor necrosis factor alpha; TNF-α: xenotropic MLV-related virus; XMRV: 8-OH-deoxy guanosine, 8-OHdG.

Lik dette:

Bli den første til å like d

Share this:

Lik dette: